載入中
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
前收盤價
US$10.395
−US$0.205 · -1.93%
盤前
US$10.21
−US$0.185 · -1.78%
10月13日 上午4:26 ET
盤中時間採用ET。市場資料可能有所延遲。
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
日內區間
目前US$10.395
52週區間
目前US$10.395
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
買進
估值
88
深度低估
情緒
53
多空交錯
風險
39
中等風險
動能
64
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
日內區間
目前US$10.395
52週區間
目前US$10.395
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6748.2萬 USD | 5388.3萬 USD | — | — | — |
| 銷貨成本 | 5.7萬 USD | — | 84.9萬 USD | — | — |
| 毛利 | 6742.5萬 USD | 5388.3萬 USD | −84.9萬 USD | — | — |
| 研究與開發 | 2.51億 USD | 1.7億 USD | 1.15億 USD | 9281.2萬 USD | 8472.1萬 USD |
| 銷售、一般及管理費用 | 1.2億 USD | 7711.1萬 USD | 5056.9萬 USD | 4705.3萬 USD | 4653.7萬 USD |
| 營業費用 | 3.71億 USD | 2.47億 USD | 1.65億 USD | 1.4億 USD | 1.31億 USD |
| 利息收入 | 2677.4萬 USD | 2284.9萬 USD | 1472.2萬 USD | 425.4萬 USD | 120.6萬 USD |
| 利息支出 | 151.2萬 USD | 161.9萬 USD | 154.9萬 USD | 22.9萬 USD | 41.4萬 USD |
| 折舊和攤銷 | 103.2萬 USD | 84.8萬 USD | 84.9萬 USD | 75.9萬 USD | 55.8萬 USD |
| 營業利益 | −3.04億 USD | −1.93億 USD | −1.66億 USD | −1.4億 USD | −1.31億 USD |
| 淨利 | −2.79億 USD | −1.74億 USD | −1.53億 USD | −1.36億 USD | −1.3億 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3541.16萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2652.28萬0.27%103.03億 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM2351.75萬0.03%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1307.25萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO831.34萬0.06%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB715.75萬0.07%108.2億 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO618.88萬0.03%180億 USD0.06%US$112.27-0.35%
Fidelity Enhanced Small Cap ETFFESM560.06萬0.08%64.1億 USD0.28%US$45.24-0.48%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
